Clinical Trials Logo

Malignant Solid Tumour clinical trials

View clinical trials related to Malignant Solid Tumour.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00801151 Terminated - Clinical trials for Malignant Solid Tumour

Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer

Start date: January 2009
Phase: Phase 1
Study type: Interventional

This is a multi-center, open-label non-randomized dose-escalation trial of vorinostat given in combination with vinorelbine. Cohorts will be treated with a fixed dose of vinorelbine (25mg/m²/week continuously, representing the schedule that has been approved). Patients eligible will be enrolled into a standard 3+3 design with a starting dose of vorinostat at 200 mg po qd 7/21 (weekly schedule). Then, further dose levels will be explored. Toxicity of the schedule will be assessed during the first cycle. Patients may receive up to 6 cycles of study medication. Blood samples will be collected at specified time points to assess pharmacokinetic endpoints.